Bladder Cancer Clinical Trial

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Summary

This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To estimate complete response at 25 weeks after registration for those with a carcinoma in situ (CIS) component and to evaluate event-free survival at 18 months in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (Ta/T1/CIS) treated with atezolizumab.

SECONDARY OBJECTIVES:

I. To estimate event-free survival at 18 months for the subset of patients with papillary cancer (Ta/T1).

II. To estimate progression-free survival, cystectomy-free survival, bladder cancer-specific survival, overall survival in all patients.

ADDITIONAL OBJECTIVES:

I. To estimate the level of agreement between local and central pathology review in terms of recurrence (for all patients) and complete response (for the CIS subset).

II. To identify markers that predict response to atezolizumab in the CIS population and that are associated with event-free survival (EFS) in patients with Ta/T1/CIS BCG-unresponsive non-muscle invasive bladder cancer. The following markers will be tested:

IIIa. Expression of PD-L1 and CD8 by immunohistochemistry (IHC). IIIb. Expression of immune signatures by ribonucleic acid (RNA)-sequencing (RNA-seq).

IIIc. Peripheral immune response by mass cytometry (CyTOF) and TruCulture.

OUTLINE:

Patients receive atezolizumab intravenously (IV) over 60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles (51 weeks) in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 12 weeks for 2 years and then every 24 weeks for 3 years.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must have histologically proven, recurrent, non-muscle invasive urothelial carcinoma of the bladder within 60 days prior to registration; the carcinoma must be stage T1 high-grade, stage CIS, or stage Ta high-grade
Patients with mixed urothelial carcinoma and a glandular and/or squamous component will be eligible for the trial, but the presence of other histologic variants, pure adenocarcinoma, or pure squamous cell carcinoma, or pure squamous carcinoma in situ will make a patient ineligible
Patients must have had all visible tumor resected completely within 60 days prior to registration; CIS disease is not expected to be completely excised; all patients must have tumor tissue from the histologic diagnosis of recurrence available for central pathology review submission; failure to submit these materials will make the patient ineligible for this study
Patients must have had cystoscopy confirming no visible papillary tumor within 21 days prior to registration; (CIS disease is not expected to have been completely excised); if the transurethral resection of bladder tumor (TURBT) or bladder biopsy falls within 21 days of registration it will fulfill this criterion
Patients must have had urine cytology within 21 days prior to registration; cytology for patients with CIS component is not expected to be negative for malignant cells; if the cytology for male patients with only Ta/T1 disease in the absence of CIS is positive for malignant cells, patient must have had a biopsy of the prostatic urethra within the previous six months
All patients with T1 urothelial carcinoma at study entry must undergo re-TURBT within 60 days prior to registration, and must have evidence of uninvolved muscularis propria in the pathologic specimen from either the first or the second TURBT; tissue from the re-resection must be submitted for central review in addition to the tissue from the first TURBT; the TURBT that identified the recurrent T1 disease may have taken place more than 60 days prior to registration but not more than 120 days; patients with high grade Ta or CIS do not require a re-TURBT, but if this is performed at the discretion of the treating physician, the second TURBT must be within 60 days of registration; there is no requirement for muscularis propria in the specimen of Ta/CIS patients, but the tissue from the first and second TURBTs must be submitted for central review; if a patient with Ta/T1 disease undergoes repeat TURBT, the patient will be stratified as having CIS if there is CIS on either TURBT
Patients must not have had urothelial carcinoma in the prostatic urethra within the previous 24 months or muscle invasive urothelial carcinoma of the bladder at any time; patients with prior urothelial carcinoma in the upper urinary tract within the previous 24 months will only be eligible if they had =< T1 carcinoma and were treated with nephroureterectomy; patients must have a computed tomography (CT) or magnetic resonance imaging (MRI) (including CT-intravenous pyelogram [IVP], CT-urogram or MR-urogram) of the abdomen and pelvis to rule out upper tract malignancy and intra-abdominal metastases within 90 days prior to registration; if a patient cannot tolerate intravenous contrast, a retrograde pyelogram should be performed within 90 days prior to registration
Patients must be deemed unfit for radical cystectomy by the treating physician, or the patient must refuse radical cystectomy, which is considered standard of care for these patients; the reason for patients not to undergo cystectomy will be clearly documented

Patients must be BCG-unresponsive; a patient is BCG-unresponsive if they meet one or more of the following criteria:

Patient has persistent or recurrent high-grade Ta/CIS urothelial carcinoma after completing therapy with at least induction BCG (>= 5 doses) and first round maintenance (>= 2 doses) or second induction BCG (>= 2 doses); both rounds of BCG must have been administered within a 12 month period; these patients must have either had high-grade Ta tumors and did not achieve a disease-free state for more than 6 months following last dose of BCG, or they had CIS and did not achieve a CR; S1605 registration must occur within 9 months of the last dose of BCG

If a patient does not meet these criteria only because the last dose of BCG was more than 9 months ago, the patient may become eligible if he/she shows histologically proven high-grade recurrence after an additional round of induction or maintenance BCG (>= 3 doses) within 9 months prior to registration

Patient has persistent or recurrent high grade T1 urothelial carcinoma after completing therapy with at least induction BCG (>= 5 doses); patients with recurrent high grade T1 urothelial carcinoma after additional rounds of BCG will also be eligible, but one round of maintenance therapy or a second induction is not a pre-requisite for these patients. Trial registration must occur within 9 months of the last dose of BCG

If a patient does not meet these criteria only because the last dose of BCG was more than 9 months ago, the patient may become eligible if he/she shows histologically proven high grade recurrence after an additional round of induction or maintenance BCG (>= 3 doses) within 9 months prior to registration
Patient achieves disease-free state at 6 month time point (i.e., complete response; presence of only low-grade tumor at this timepoint is still considered complete response) after induction and maintenance (or second round of induction) BCG but later experiences a high-grade Ta/T1 recurrence (with or without concomitant CIS) within 6 months after the last dose of BCG or recurrent CIS (in absence of concomitant Ta/T1 tumor) within 12 months after the last BCG dose; the time of eligibility is measured from the last dose of BCG to the time of disease recurrence; the patient must be registered on the trial within 60 days of this recurrence, or within 60 days of a re-TURBT if indicated
All adverse events associated with any prior surgery and intravesical therapy must have resolved to grade =< 2 prior to registration
Absolute neutrophil count (ANC) >= 1,500 microliter (mcL) (within 42 days prior to registration)
Platelets >= 100,000/mcL (within 42 days prior to registration)
Hemoglobin >= 9 g/dL (within 42 days prior to registration)
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL) (within 42 days prior to registration)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x IULN (within 42 days prior to registration)
Serum creatinine =< 1.5 ULN OR measured or calculated creatinine clearance >= 30 mL/min (within 42 days prior to registration)
Patients must have Zubrod performance status =< 2
Patients must have a baseline electrocardiograph (ECG) performed within 42 days prior to registration

Patients positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:

A stable regimen of highly active anti-retroviral therapy (HAART)
No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
No other prior malignancy is allowed except, for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years
Patients must be offered the opportunity to participate in specimen banking for future studies, to include translational medicine studies
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
As a part of the oncology patient enrollment network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

Exclusion Criteria:

Patients must not have had prior systemic chemotherapy for bladder cancer or systemic immunotherapy, including, but not limited to interferon alfa-2b, high dose interleukin 2 (IL-2), pegylated interferon (PEG-IFN), PD-1, anti-PD-L1, intra-tumoral; patients must not have had vaccine therapies within 6 weeks prior to registration; patients must not have received or be planning to receive any of the prohibited therapies during protocol treatment; prior intravesical administration of chemotherapy, interferon, Vicinium (VB4-485), BC-819 or Instiladrin (rAd-interferon-alpha/Syn3) is allowed if all other criteria are met and the last administration was >= 30 days before registration
Patients must not be planning to receive concomitant other biologic therapy, radiation therapy, intravesical chemotherapy, surgery, or other anti-cancer therapy while on this protocol
Patients must not have received any prior radiation to the bladder for bladder cancer
Patients must not have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 4 weeks prior to registration; exceptions: (1) patients may have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea); (2) the use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed

Patients must not have received a live, attenuated vaccine within 4 weeks before registration or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab

Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study
Patients must not require treatment with a RANKL inhibitor (e.g. denosumab) who cannot discontinue it before treatment with atezolizumab
Patient must not have history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis
Patients must not have an active infection requiring oral or IV antibiotics within 14 days prior to registration; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
Patients must not have severe infections within 28 days prior to registration, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
Patients must not have active autoimmune disease that has required systemic treatment in past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis
Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation
Patient must not have active tuberculosis

Patients must not have active hepatitis B (chronic or acute) or active hepatitis C infection

Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible
Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA
Patients must not be pregnant or nursing due to the potential teratogenic side effects of the protocol treatment; administration of atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Due to the potential drug reaction with atezolizumab, patients must not be known to be allergic to Chinese hamster egg or ovaries

Study is for people with:

Bladder Cancer

Phase:

Phase 2

Estimated Enrollment:

172

Study ID:

NCT02844816

Recruitment Status:

Active, not recruiting

Sponsor:

National Cancer Institute (NCI)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 232 Locations for this study

See Locations Near You

Southern Cancer Center PC-Daphne
Daphne Alabama, 36526, United States
Southern Cancer Center PC-Mobile
Mobile Alabama, 36607, United States
Southern Cancer Center PC-Providence
Mobile Alabama, 36608, United States
Southern Cancer Center PC-Springhill
Mobile Alabama, 36608, United States
Mayo Clinic in Arizona
Scottsdale Arizona, 85259, United States
University of Arizona Cancer Center-Orange Grove Campus
Tucson Arizona, 85704, United States
Banner University Medical Center - Tucson
Tucson Arizona, 85719, United States
University of Arizona Cancer Center-North Campus
Tucson Arizona, 85719, United States
John L McClellan Memorial Veterans Hospital
Little Rock Arkansas, 72205, United States
UC San Diego Moores Cancer Center
La Jolla California, 92093, United States
Los Angeles General Medical Center
Los Angeles California, 90033, United States
USC / Norris Comprehensive Cancer Center
Los Angeles California, 90033, United States
Stanford Cancer Institute Palo Alto
Palo Alto California, 94304, United States
Eisenhower Medical Center
Rancho Mirage California, 92270, United States
University of California Davis Comprehensive Cancer Center
Sacramento California, 95817, United States
UCSF Medical Center-Mission Bay
San Francisco California, 94158, United States
UCHealth University of Colorado Hospital
Aurora Colorado, 80045, United States
Kaiser Permanente-Franklin
Denver Colorado, 80205, United States
Kaiser Permanente-Rock Creek
Lafayette Colorado, 80026, United States
Kaiser Permanente-Lone Tree
Lone Tree Colorado, 80124, United States
Greenwich Hospital
Greenwich Connecticut, 06830, United States
Yale University
New Haven Connecticut, 06520, United States
Veterans Affairs Connecticut Healthcare System-West Haven Campus
West Haven Connecticut, 06516, United States
Delaware Clinical and Laboratory Physicians PA
Newark Delaware, 19713, United States
Helen F Graham Cancer Center
Newark Delaware, 19713, United States
Medical Oncology Hematology Consultants PA
Newark Delaware, 19713, United States
Christiana Care Health System-Christiana Hospital
Newark Delaware, 19718, United States
Christiana Care Health System-Wilmington Hospital
Wilmington Delaware, 19801, United States
MedStar Washington Hospital Center
Washington District of Columbia, 20010, United States
George Washington University Medical Center
Washington District of Columbia, 20037, United States
Mount Sinai Comprehensive Cancer Center at Aventura
Aventura Florida, 33180, United States
University of Florida Health Science Center - Gainesville
Gainesville Florida, 32610, United States
Mount Sinai Medical Center
Miami Beach Florida, 33140, United States
Indian River Medical Center
Vero Beach Florida, 32960, United States
Emory University Hospital/Winship Cancer Institute
Atlanta Georgia, 30322, United States
Atlanta VA Medical Center
Decatur Georgia, 30033, United States
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah Georgia, 31405, United States
Pali Momi Medical Center
'Aiea Hawaii, 96701, United States
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu Hawaii, 96813, United States
Island Urology
Honolulu Hawaii, 96813, United States
Queen's Cancer Cenrer - POB I
Honolulu Hawaii, 96813, United States
Queen's Medical Center
Honolulu Hawaii, 96813, United States
Straub Clinic and Hospital
Honolulu Hawaii, 96813, United States
University of Hawaii Cancer Center
Honolulu Hawaii, 96813, United States
Queen's Cancer Center - Kuakini
Honolulu Hawaii, 96817, United States
Kapiolani Medical Center for Women and Children
Honolulu Hawaii, 96826, United States
Saint Alphonsus Cancer Care Center-Boise
Boise Idaho, 83706, United States
Saint Luke's Cancer Institute - Boise
Boise Idaho, 83712, United States
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell Idaho, 83605, United States
Walter Knox Memorial Hospital
Emmett Idaho, 83617, United States
Idaho Urologic Institute-Meridian
Meridian Idaho, 83642, United States
Saint Luke's Cancer Institute - Meridian
Meridian Idaho, 83642, United States
Saint Alphonsus Cancer Care Center-Nampa
Nampa Idaho, 83687, United States
Saint Luke's Cancer Institute - Twin Falls
Twin Falls Idaho, 83301, United States
Rush - Copley Medical Center
Aurora Illinois, 60504, United States
Illinois CancerCare-Bloomington
Bloomington Illinois, 61704, United States
Illinois CancerCare-Canton
Canton Illinois, 61520, United States
Illinois CancerCare-Carthage
Carthage Illinois, 62321, United States
Centralia Oncology Clinic
Centralia Illinois, 62801, United States
Northwestern University
Chicago Illinois, 60611, United States
Carle at The Riverfront
Danville Illinois, 61832, United States
Cancer Care Specialists of Illinois - Decatur
Decatur Illinois, 62526, United States
Decatur Memorial Hospital
Decatur Illinois, 62526, United States
Carle Physician Group-Effingham
Effingham Illinois, 62401, United States
Crossroads Cancer Center
Effingham Illinois, 62401, United States
Elmhurst Memorial Hospital
Elmhurst Illinois, 60126, United States
Illinois CancerCare-Eureka
Eureka Illinois, 61530, United States
Illinois CancerCare-Galesburg
Galesburg Illinois, 61401, United States
Edward Hines Jr VA Hospital
Hines Illinois, 60141, United States
Illinois CancerCare-Kewanee Clinic
Kewanee Illinois, 61443, United States
Illinois CancerCare-Macomb
Macomb Illinois, 61455, United States
Carle Physician Group-Mattoon/Charleston
Mattoon Illinois, 61938, United States
Loyola University Medical Center
Maywood Illinois, 60153, United States
Good Samaritan Regional Health Center
Mount Vernon Illinois, 62864, United States
Edward Hospital/Cancer Center
Naperville Illinois, 60540, United States
Illinois CancerCare-Ottawa Clinic
Ottawa Illinois, 61350, United States
Illinois CancerCare-Pekin
Pekin Illinois, 61554, United States
Illinois CancerCare-Peoria
Peoria Illinois, 61615, United States
Methodist Medical Center of Illinois
Peoria Illinois, 61636, United States
OSF Saint Francis Medical Center
Peoria Illinois, 61637, United States
Illinois CancerCare-Peru
Peru Illinois, 61354, United States
Edward Hospital/Cancer Center?Plainfield
Plainfield Illinois, 60585, United States
Illinois CancerCare-Princeton
Princeton Illinois, 61356, United States
Southern Illinois University School of Medicine
Springfield Illinois, 62702, United States
Springfield Clinic
Springfield Illinois, 62702, United States
Memorial Medical Center
Springfield Illinois, 62781, United States
Carle Cancer Center
Urbana Illinois, 61801, United States
The Carle Foundation Hospital
Urbana Illinois, 61801, United States
Rush-Copley Healthcare Center
Yorkville Illinois, 60560, United States
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis Indiana, 46202, United States
Community Cancer Center East
Indianapolis Indiana, 46219, United States
Community Cancer Center South
Indianapolis Indiana, 46227, United States
Community Cancer Center North
Indianapolis Indiana, 46256, United States
Community Howard Regional Health
Kokomo Indiana, 46904, United States
Reid Health
Richmond Indiana, 47374, United States
Cancer Center of Kansas - Chanute
Chanute Kansas, 66720, United States
Cancer Center of Kansas - Dodge City
Dodge City Kansas, 67801, United States
Cancer Center of Kansas - El Dorado
El Dorado Kansas, 67042, United States
Cancer Center of Kansas - Fort Scott
Fort Scott Kansas, 66701, United States
HaysMed
Hays Kansas, 67601, United States
Cancer Center of Kansas-Independence
Independence Kansas, 67301, United States
University of Kansas Cancer Center
Kansas City Kansas, 66160, United States
Cancer Center of Kansas-Kingman
Kingman Kansas, 67068, United States
Lawrence Memorial Hospital
Lawrence Kansas, 66044, United States
Cancer Center of Kansas-Liberal
Liberal Kansas, 67905, United States
Cancer Center of Kansas-Manhattan
Manhattan Kansas, 66502, United States
Cancer Center of Kansas - McPherson
McPherson Kansas, 67460, United States
Cancer Center of Kansas - Newton
Newton Kansas, 67114, United States
Olathe Health Cancer Center
Olathe Kansas, 66061, United States
Cancer Center of Kansas - Parsons
Parsons Kansas, 67357, United States
Ascension Via Christi - Pittsburg
Pittsburg Kansas, 66762, United States
Cancer Center of Kansas - Pratt
Pratt Kansas, 67124, United States
Cancer Center of Kansas - Salina
Salina Kansas, 67401, United States
Salina Regional Health Center
Salina Kansas, 67401, United States
University of Kansas Health System Saint Francis Campus
Topeka Kansas, 66606, United States
Cancer Center of Kansas - Wellington
Wellington Kansas, 67152, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood Kansas, 66205, United States
Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita Kansas, 67208, United States
Ascension Via Christi Hospitals Wichita
Wichita Kansas, 67214, United States
Cancer Center of Kansas - Wichita
Wichita Kansas, 67214, United States
Cancer Center of Kansas - Winfield
Winfield Kansas, 67156, United States
University of Kentucky/Markey Cancer Center
Lexington Kentucky, 40536, United States
East Jefferson General Hospital
Metairie Louisiana, 70006, United States
LSU Healthcare Network / Metairie Multi-Specialty Clinic
Metairie Louisiana, 70006, United States
Louisiana State University Health Science Center
New Orleans Louisiana, 70112, United States
LSU Health Sciences Center at Shreveport
Shreveport Louisiana, 71103, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore Maryland, 21287, United States
Boston Medical Center
Boston Massachusetts, 02118, United States
Lowell General Hospital
Lowell Massachusetts, 01854, United States
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor Michigan, 48106, United States
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton Michigan, 48114, United States
Trinity Health Medical Center - Brighton
Brighton Michigan, 48114, United States
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton Michigan, 48188, United States
Trinity Health Medical Center - Canton
Canton Michigan, 48188, United States
Caro Cancer Center
Caro Michigan, 48723, United States
Saint Joseph Mercy Chelsea
Chelsea Michigan, 48118, United States
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea Michigan, 48118, United States
Hematology Oncology Consultants-Clarkston
Clarkston Michigan, 48346, United States
Newland Medical Associates-Clarkston
Clarkston Michigan, 48346, United States
Michigan State University Clinical Center
East Lansing Michigan, 48824, United States
Genesee Cancer and Blood Disease Treatment Center
Flint Michigan, 48503, United States
Genesee Hematology Oncology PC
Flint Michigan, 48503, United States
Genesys Hurley Cancer Institute
Flint Michigan, 48503, United States
University of Michigan Health - Sparrow Lansing
Lansing Michigan, 48912, United States
Saint Mary's Oncology/Hematology Associates of Marlette
Marlette Michigan, 48453, United States
Newland Medical Associates-Pontiac
Pontiac Michigan, 48341, United States
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac Michigan, 48341, United States
Ascension Saint Mary's Hospital
Saginaw Michigan, 48601, United States
Oncology Hematology Associates of Saginaw Valley PC
Saginaw Michigan, 48604, United States
Saint Mary's Oncology/Hematology Associates of West Branch
West Branch Michigan, 48661, United States
Huron Gastroenterology PC
Ypsilanti Michigan, 48106, United States
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti Michigan, 48197, United States
Fairview Ridges Hospital
Burnsville Minnesota, 55337, United States
Essentia Health - Deer River Clinic
Deer River Minnesota, 56636, United States
Essentia Health Cancer Center
Duluth Minnesota, 55805, United States
Essentia Health Saint Mary's Medical Center
Duluth Minnesota, 55805, United States
Miller-Dwan Hospital
Duluth Minnesota, 55805, United States
Saint Luke's Hospital of Duluth
Duluth Minnesota, 55805, United States
Fairview Southdale Hospital
Edina Minnesota, 55435, United States
Essentia Health Hibbing Clinic
Hibbing Minnesota, 55746, United States
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud Minnesota, 56303, United States
Saint Cloud Hospital
Saint Cloud Minnesota, 56303, United States
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park Minnesota, 55416, United States
Essentia Health Virginia Clinic
Virginia Minnesota, 55792, United States
Fairview Lakes Medical Center
Wyoming Minnesota, 55092, United States
Parkland Health Center-Bonne Terre
Bonne Terre Missouri, 63628, United States
Saint Francis Medical Center
Cape Girardeau Missouri, 63703, United States
Southeast Cancer Center
Cape Girardeau Missouri, 63703, United States
MU Health - University Hospital/Ellis Fischel Cancer Center
Columbia Missouri, 65212, United States
Kansas City Veterans Affairs Medical Center
Kansas City Missouri, 64128, United States
Missouri Baptist Medical Center
Saint Louis Missouri, 63131, United States
Sainte Genevieve County Memorial Hospital
Sainte Genevieve Missouri, 63670, United States
Missouri Baptist Sullivan Hospital
Sullivan Missouri, 63080, United States
BJC Outpatient Center at Sunset Hills
Sunset Hills Missouri, 63127, United States
Benefis Sletten Cancer Institute
Great Falls Montana, 59405, United States
Saint Patrick Hospital - Community Hospital
Missoula Montana, 59802, United States
Nebraska Medicine-Village Pointe
Omaha Nebraska, 68118, United States
University of Nebraska Medical Center
Omaha Nebraska, 68198, United States
Cancer and Blood Specialists-Henderson
Henderson Nevada, 89052, United States
Ann M Wierman MD LTD
Las Vegas Nevada, 89128, United States
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas Nevada, 89128, United States
OptumCare Cancer Care at MountainView
Las Vegas Nevada, 89128, United States
Comprehensive Cancer Centers of Nevada - Town Center
Las Vegas Nevada, 89144, United States
Comprehensive Cancer Centers of Nevada
Las Vegas Nevada, 89148, United States
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas Nevada, 89169, United States
Renown Regional Medical Center
Reno Nevada, 89502, United States
Robert Wood Johnson University Hospital Somerset
Somerville New Jersey, 08876, United States
Roswell Park Cancer Institute
Buffalo New York, 14263, United States
Mount Sinai West
New York New York, 10019, United States
NYP/Weill Cornell Medical Center
New York New York, 10065, United States
University of Rochester
Rochester New York, 14642, United States
State University of New York Upstate Medical University
Syracuse New York, 13210, United States
Southeastern Medical Oncology Center-Clinton
Clinton North Carolina, 28328, United States
Southeastern Medical Oncology Center-Goldsboro
Goldsboro North Carolina, 27534, United States
Wayne Memorial Hospital
Goldsboro North Carolina, 27534, United States
Southeastern Medical Oncology Center-Jacksonville
Jacksonville North Carolina, 28546, United States
WG Hefner VA Medical Center
Salisbury North Carolina, 28144, United States
Wake Forest University Health Sciences
Winston-Salem North Carolina, 27157, United States
Sanford Bismarck Medical Center
Bismarck North Dakota, 58501, United States
Sanford Broadway Medical Center
Fargo North Dakota, 58122, United States
Sanford Roger Maris Cancer Center
Fargo North Dakota, 58122, United States
Dayton Physician LLC - Englewood
Dayton Ohio, 45415, United States
Miami Valley Hospital North
Dayton Ohio, 45415, United States
Kettering Medical Center
Kettering Ohio, 45429, United States
Saint Rita's Medical Center
Lima Ohio, 45801, United States
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States
Mercy Hospital Oklahoma City
Oklahoma City Oklahoma, 73120, United States
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa Oklahoma, 74146, United States
Saint Alphonsus Medical Center-Baker City
Baker City Oregon, 97814, United States
Legacy Mount Hood Medical Center
Gresham Oregon, 97030, United States
Saint Alphonsus Medical Center-Ontario
Ontario Oregon, 97914, United States
Legacy Good Samaritan Hospital and Medical Center
Portland Oregon, 97210, United States
Legacy Meridian Park Hospital
Tualatin Oregon, 97062, United States
Christiana Care Health System-Concord Health Center
Chadds Ford Pennsylvania, 19317, United States
Allegheny General Hospital
Pittsburgh Pennsylvania, 15212, United States
Prisma Health Cancer Institute - Spartanburg
Boiling Springs South Carolina, 29316, United States
Prisma Health Cancer Institute - Laurens
Clinton South Carolina, 29325, United States
Prisma Health Cancer Institute - Easley
Easley South Carolina, 29640, United States
Prisma Health Cancer Institute - Butternut
Greenville South Carolina, 29605, United States
Prisma Health Cancer Institute - Faris
Greenville South Carolina, 29605, United States
Prisma Health Greenville Memorial Hospital
Greenville South Carolina, 29605, United States
Prisma Health Cancer Institute - Eastside
Greenville South Carolina, 29615, United States
Prisma Health Cancer Institute - Greer
Greer South Carolina, 29650, United States
Prisma Health Cancer Institute - Seneca
Seneca South Carolina, 29672, United States
Sanford Cancer Center Oncology Clinic
Sioux Falls South Dakota, 57104, United States
Sanford USD Medical Center - Sioux Falls
Sioux Falls South Dakota, 57117, United States
University of Texas Medical Branch
Galveston Texas, 77555, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston Texas, 77030, United States
UTMB Cancer Center at Victory Lakes
League City Texas, 77573, United States
Audie L Murphy VA Hospital
San Antonio Texas, 78229, United States
University Hospital
San Antonio Texas, 78229, United States
University of Texas Health Science Center at San Antonio
San Antonio Texas, 78229, United States
Farmington Health Center
Farmington Utah, 84025, United States
Huntsman Cancer Institute/University of Utah
Salt Lake City Utah, 84112, United States
South Jordan Health Center
South Jordan Utah, 84009, United States
Centra Alan B Pearson Regional Cancer Center
Lynchburg Virginia, 24501, United States
Virginia Commonwealth University/Massey Cancer Center
Richmond Virginia, 23298, United States
Swedish Medical Center-First Hill
Seattle Washington, 98122, United States
Legacy Salmon Creek Hospital
Vancouver Washington, 98686, United States
West Virginia University Charleston Division
Charleston West Virginia, 25304, United States
Duluth Clinic Ashland
Ashland Wisconsin, 54806, United States
Aurora Cancer Care-Southern Lakes VLCC
Burlington Wisconsin, 53105, United States
Marshfield Clinic-Chippewa Center
Chippewa Falls Wisconsin, 54729, United States
Marshfield Medical Center-EC Cancer Center
Eau Claire Wisconsin, 54701, United States
Aurora Health Center-Fond du Lac
Fond Du Lac Wisconsin, 54937, United States
Aurora Health Care Germantown Health Center
Germantown Wisconsin, 53022, United States
Aurora Cancer Care-Grafton
Grafton Wisconsin, 53024, United States
Aurora BayCare Medical Center
Green Bay Wisconsin, 54311, United States
Aurora Cancer Care-Kenosha South
Kenosha Wisconsin, 53142, United States
Marshfield Medical Center - Ladysmith
Ladysmith Wisconsin, 54848, United States
University of Wisconsin Carbone Cancer Center - University Hospital
Madison Wisconsin, 53792, United States
Aurora Bay Area Medical Group-Marinette
Marinette Wisconsin, 54143, United States
Marshfield Medical Center-Marshfield
Marshfield Wisconsin, 54449, United States
Aurora Cancer Care-Milwaukee
Milwaukee Wisconsin, 53209, United States
Aurora Saint Luke's Medical Center
Milwaukee Wisconsin, 53215, United States
Aurora Sinai Medical Center
Milwaukee Wisconsin, 53233, United States
Marshfield Clinic-Minocqua Center
Minocqua Wisconsin, 54548, United States
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh Wisconsin, 54904, United States
Aurora Cancer Care-Racine
Racine Wisconsin, 53406, United States
Marshfield Medical Center-Rice Lake
Rice Lake Wisconsin, 54868, United States
Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan Wisconsin, 53081, United States
Marshfield Medical Center-River Region at Stevens Point
Stevens Point Wisconsin, 54482, United States
Aurora Medical Center in Summit
Summit Wisconsin, 53066, United States
Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers Wisconsin, 54241, United States
Marshfield Clinic-Wausau Center
Wausau Wisconsin, 54401, United States
Aurora Cancer Care-Milwaukee West
Wauwatosa Wisconsin, 53226, United States
Aurora West Allis Medical Center
West Allis Wisconsin, 53227, United States
Marshfield Medical Center - Weston
Weston Wisconsin, 54476, United States
Marshfield Clinic - Wisconsin Rapids Center
Wisconsin Rapids Wisconsin, 54494, United States
Cross Cancer Institute
Edmonton Alberta, T6G 1, Canada
The Research Institute of the McGill University Health Centre (MUHC)
Montreal Quebec, H3H 2, Canada
Allan Blair Cancer Centre
Regina Saskatchewan, S4T 7, Canada

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 2

Estimated Enrollment:

172

Study ID:

NCT02844816

Recruitment Status:

Active, not recruiting

Sponsor:


National Cancer Institute (NCI)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.